- Home
- ALXO vs SOL Comparison
ALXO vs SOL Comparison
Compare ALXO & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- SOL
- Stock Information
- Founded
- ALXO 2015
- SOL 2005
- Country
- ALXO United States
- SOL United States
- Employees
- ALXO N/A
- SOL N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- SOL Semiconductors
- Sector
- ALXO Health Care
- SOL Technology
- Exchange
- ALXO Nasdaq
- SOL Nasdaq
- Market Cap
- ALXO 76.5M
- SOL 89.7M
- IPO Year
- ALXO 2020
- SOL 2008
- Fundamental
- Price
- ALXO $1.12
- SOL $1.66
- Analyst Decision
- ALXO Buy
- SOL Buy
- Analyst Count
- ALXO 6
- SOL 3
- Target Price
- ALXO $6.64
- SOL $3.83
- AVG Volume (30 Days)
- ALXO 769.2K
- SOL 181.6K
- Earning Date
- ALXO 03-06-2025
- SOL 03-27-2025
- Dividend Yield
- ALXO N/A
- SOL N/A
- EPS Growth
- ALXO N/A
- SOL N/A
- EPS
- ALXO N/A
- SOL N/A
- Revenue
- ALXO N/A
- SOL $102,489,000.00
- Revenue This Year
- ALXO N/A
- SOL N/A
- Revenue Next Year
- ALXO N/A
- SOL $47.66
- P/E Ratio
- ALXO N/A
- SOL N/A
- Revenue Growth
- ALXO N/A
- SOL 25.98
- 52 Week Low
- ALXO $0.96
- SOL $1.41
- 52 Week High
- ALXO $17.83
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- ALXO 38.53
- SOL 36.27
- Support Level
- ALXO $1.00
- SOL $1.67
- Resistance Level
- ALXO $1.22
- SOL $1.79
- Average True Range (ATR)
- ALXO 0.09
- SOL 0.08
- MACD
- ALXO 0.00
- SOL -0.00
- Stochastic Oscillator
- ALXO 35.12
- SOL 18.52
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.